Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Chugai Drops Five Early-Stage Programs to Refocus Pipeline
Chugai Pharmaceutical has scrapped the in-house development of five drug candidates among 14 projects in PI-II, President and CEO Osamu Okuda said at the company’s earnings briefing on July 24. The decision reflects a reprioritization of the pipeline based on…
To read the full story
Related Article
BUSINESS
- Shionogi’s CEO Pay Up at 302 Million Yen in FY2025
June 22, 2026
- J-TEC Sets Up German Unit to Expand LabCyte Biz in Europe
June 22, 2026
- Daiichi Sankyo CEO’s Pay Rises to 273 Million Yen in FY2025
June 22, 2026
- Shionogi/F2G’s Novel Antifungal Makes Mark, New Option in Resistant Cases
June 19, 2026
- Axcelead Joins Lilly’s TuneLab AI Drug Discovery Platform
June 19, 2026
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…